The Week in Healthcare: Another Alzheimer’s Drug Fails as New Antitumor Drug Sees Light of the Day 

 enero 25, 2022

El contenido del artículo


This week Mexico’s third presidential debate hogged the spotlight. But civil institutions lamented that there was much ado about nothing concerning healthcare. Also, an NGO raised the alarm about the country’s growing rate of teen pregnancy. The Mexican commission against addiction joined beer manufacturers to prevent underage drinking and Mexico signed collaboration agreement with Denmark about mental health.

Mexican researchers announced an antibacterial hydrogel. Sanofi launched its first antitumor drug in many years but another Alzheimer’s drug failed in its phase III trial.

Furthermore, a recent report raised doubts on results from the Stanford prison experiment, an iconic study on human nature that has become a cornerstone of psychology classes and even permeated popular culture. And ICON’s Karen Hahn spoke to Mexico Health Review on the company’s plans for Mexico and the advantages the country can bring to CROs.

Now, jump in last week’s highlights:


The third presidential debate was held on Tuesday. While all candidates remarked on the importance of unifying Mexico’s healthcare system and reiterated their previously-presented proposals, civil organizations decried the lack of clear policies to achieve said goals.

Mexico and Denmark extend collaboration agreement in healthcare. This collaboration includes research projects in mental health and suicide prevention.

The NGO Ipas decried the growing pregnancy rate of Mexican girls between 10 and 14 years old. The organization reported a total of 11,808 pregnancies girls in that age range in 2016.

Researchers from UNAM’s Department of Chemistry developed an antibacterial hydrogel that aids in the skin’s healing process.

The National Commission Against Addiction (Conadic) joined forces with Mexican Beer Manufacturers “Cerveceros de Mexico” to prevent underage drinking.


Eli Lilly and AstraZeneca reported the failure of another potential Alzheimer’s drug, lanabecestat. This failure is just the latest among many, raising questions whether the current approach to the disease is correct at all.

Sanofi, alongside Regeneron Pharmaceuticals, launched its first antitumor drug in several years for the treatment of skin cancer, cemiplimab. The drug manufacturer expects for cemiplimab to eventually be used to fight lung cancer.


There are no reviews yet. Be the first one to write one.